CSIMarket
 
Fate Therapeutics Inc   (FATE)
Other Ticker:  
 
 
Price: $7.0400 $-0.45 -6.008%
Day's High: $7.5 Week Perf: -8.09 %
Day's Low: $ 6.95 30 Day Perf: -0.56 %
Volume (M): 2,265 52 Wk High: $ 8.83
Volume (M$): $ 15,948 52 Wk Avg: $4.28
Open: $7.49 52 Wk Low: $1.63



 Market Capitalization (Millions $) 694
 Shares Outstanding (Millions) 99
 Employees 208
 Revenues (TTM) (Millions $) 106
 Net Income (TTM) (Millions $) -173
 Cash Flow (TTM) (Millions $) -49
 Capital Exp. (TTM) (Millions $) 13

Fate Therapeutics Inc
Fate Therapeutics Inc is a biopharmaceutical company that develops advanced cellular therapies that can replace or repair damaged cells in people suffering from severe diseases.
The company is based in San Diego, California, and was founded in 2007.
The company's innovative approach to therapy involves taking cells from a patient's body, engineering them to become specific types of cells, and then reintroducing them into the patient's body, where they can replace or repair damaged cells.
This approach offers a potential solution to many severe diseases, including cancer, genetic disorders, and autoimmune diseases.
Fate Therapeutics Inc's main product is FT516, a treatment designed to replace natural killer cells that work to identify and destroy cancer cells in the body with healthy cells produced outside the body.
They also have other products in development, including FT500, a cancer-killing cell therapy, and FT819, a CAR T-cell therapy for B-cell malignancies.
The company has a strong focus on research and development, and they have partnerships with many leading medical and academic institutions worldwide.
They have also established a strong intellectual property portfolio, which includes over 300 patents and patent applications in the field of cellular therapy.
In summary, Fate Therapeutics Inc is a cutting-edge biopharmaceutical company that develops advanced cellular therapies that can provide a potential cure for many severe diseases.
They have a strong focus on research, development, and intellectual property, making them a leader in the field of cellular therapy.


   Company Address: 12278 Scripps Summit Drive San Diego 92131 CA
   Company Phone Number: 875-1800   Stock Exchange / Ticker: NASDAQ FATE
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Fate Therapeutics Boosts Employee Retention with Inducement Award, Showing Confidence in Stem Cell Therapies

Published Tue, Mar 5 2024 9:01 PM UTC



In a recent press release, Fate Therapeutics, a prominent clinical-stage biopharmaceutical company, disclosed the granting of a non-qualified stock option to a newly-hired employee. The option allows the employee to purchase 40,000 shares of the company's common stock at a specified exercise price. This strategic move, made under Nasdaq Listing Rule 5635(c)(4), aim...

Shares

Fate Therapeutics Grants RSUs to Spark Talent Growth and Patient Impact

Published Fri, Feb 2 2024 9:01 PM UTC

Fate Therapeutics Grants New Employee Inducement Awards: Impact on Company Shares Assessed
San Diego-based biopharmaceutical company, Fate Therapeutics, has recently announced the granting of restricted stock units (RSUs) to two newly-hired non-executive employees. The RSUs, totaling 32,600 shares, have been approved by the Compensation Committee of the Company's Board ...

Clinical Study

Revolutionizing Cancer Treatment: Fate Therapeutics Leads the Charge with Phase 1 Trial of iPSC-Derived CAR T-cell Therapy

Published Mon, Jan 8 2024 1:01 PM UTC

San Diego-based biopharmaceutical company Fate Therapeutics, in conjunction with Ono Pharmaceutical Co., recently announced the initiation of a groundbreaking Phase 1 Clinical Trial for cellular immunotherapy FT825/ONO-8250 in patients battling HER2-expressing advanced solid tumors. Encompassing a novel HER2-targeted antigen-binding domain, this innovative product candidate ...

Fate Therapeutics Inc

Fate Therapeutics Inc Witnesses Remarkable Vanishing Losses in Q3 of 2023, Setting a Promising Trend for Investors



Fate Therapeutics Inc, a leading biotechnology company, has experienced significant fluctuations in its stock performance over the past few trading days. While the recent increase of 38.15% is noteworthy, the shares have witnessed a decline of -76.5% year-to-date. Additionally, the company's stock is currently trading -65.4% below its 52-week average on the NASDAQ. To gain a better understanding of the outlook for Fate Therapeutics Inc, let's delve into its recent financial results and evaluate their potential impact on the company's future.
1. Improvement in Earnings:
During the July to September 2023 interval, Fate Therapeutics Inc achieved a significant improvement in earnings. Its loss per share decreased from $-0.86 a year ago to $-0.46 per share. Furthermore, the previous reporting period saw a positive shift in income per share from $-0.54 to the current level, indicating a positive trend in profitability.

Fate Therapeutics Inc

Challenging Second Quarter of 2023 Puts Fate Therapeutics Inc in a Serious Struggle

Over the course of the last five trading days, Fate Therapeutics Inc (FATE) shares experienced a decrease of -2.32%. This decline adds to an already difficult year for the company, as its year-to-date performance now stands at -58.6%. While this drop in stock price may cause concern for investors, it is important to consider the broader context in which FATE operates.
FATE currently trades 3.3% above its 52-week low, suggesting that it is far from its lowest point and may have the potential for a rebound in the future. However, investors should approach this cautiously and assess all relevant factors before making any investment decisions.






 

Fate Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com